

August 28, 2023



## SCYNEXIS to Participate in September Investor Conferences

JERSEY CITY, N.J., Aug. 28, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that management will participate in the following investor conferences.

Event: H.C. Wainwright 25<sup>th</sup> Annual Global Investment Conference  
Format: Company presentation and 1-on-1 meetings  
Date: September 12<sup>th</sup>, 2023  
Time: 9:00 A.M. E.T.  
Location: New York, NY  
Registration: [Link](#)

Event: Cantor Fitzgerald Global Healthcare Conference  
Format: Fireside chat and 1-on-1 meetings  
Date: September 28<sup>th</sup>, 2023  
Time: 1:50 P.M. E.T.  
Location: New York, NY  
Registration: [Link](#)

### About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS is developing its proprietary class of enfumafungin-derived antifungal compounds ("fungerps") as broad-spectrum, systemic antifungal agents for multiple fungal indications. The U.S. Food and Drug Administration (FDA) approved the first representative of this antifungal class, BREXAFEMME<sup>®</sup> (ibrexafungerp tablets), in June 2021 for its first indication in vulvovaginal candidiasis (VVC), followed by a second indication in November 2022 for reduction in the incidence of recurrent VVC. Late-stage clinical investigation of ibrexafungerp for the treatment of life-threatening invasive fungal infections is ongoing. Additional assets in the novel "fungerp" class of antifungals are currently in pre-clinical and discovery phase, including the compound SCY-247. For more information, visit [www.scynexis.com](http://www.scynexis.com).

**CONTACT:**  
**Investor Relations**  
Irina Koffler  
LifeSci Advisors

Tel: (646) 970-4681  
[ikoffler@lifesciadvisors.com](mailto:ikoffler@lifesciadvisors.com)

SCYNEXIS

Source: Scynexis